Holen Sie sich die Stockscreener-App
15.16
1.34%
0.20
Handel nachbörslich:
15.14
-0.02
-0.13%
Schlusskurs vom Vortag:
$14.96
Offen:
$15.0086
24-Stunden-Volumen:
3,522
Relative Volume:
0.88
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.86%
1M Leistung:
+1.40%
6M Leistung:
-4.41%
1J Leistung:
+41.55%
1-Tages-Spanne:
$15.01
$15.16
1-Wochen-Bereich:
$14.58
$15.16
52-Wochen-Spanne:
$9.5201
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Firmenname
Range Cancer Therapeutics Etf
Sektor
Branche
Telefon
-
Adresse
-
Range Cancer Therapeutics Etf Aktie (CNCR) Neueste Nachrichten
(CNCR) Trading Report - Stock Traders Daily
The 5 Best Biotech ETFs of 2024 - TradingView
(CNCR) Investment Report - Stock Traders Daily
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
(CNCR) Investment Analysis - Stock Traders Daily
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market (SMMT) - Seeking Alpha
7 Best-Performing Biotech ETFs for November 2024 - NerdWallet
Trackinsight ETF data from 23rd to 27th September, 2024 - ETF Express
(CNCR) Investment Analysis and Advice - Stock Traders Daily
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Roundhill Investments Surpasses $2 Billion AUM Milestone – Company Announcement - Financial Times
5 ETFs That Led the Rebound on Monday - Yahoo Finance
IPO Roundup: Bicara Therapeutics, Kairos Pharma and more (NYSEARCA:IPO) - Seeking Alpha
Trading (CNCR) With Integrated Risk Controls - Stock Traders Daily
Cellectis: Cheap With Promising But Speculative Cancer Therapies (NASDAQ:CLLS) - Seeking Alpha
Best-Performing ETF Areas of Past Week - MSN
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology (TCRX) - Seeking Alpha
Why It May Be 'Just Right' to Invest in Cancer Therapeutics Development Stocks Now - Nasdaq
3 Top-Ranked ETFs Under $20 for Your Portfolio - MSN
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Invest in Hope, Invest in Life - Nasdaq
5 Top-Ranked ETFs to Buy at a Bargain - Yahoo Finance
Wall Street indexes rise after strong jobs data - Yahoo News Canada
VIXY Jumped 7.3% Last Week - Yahoo Finance
SPY Led Inflows Last Week as Leveraged Funds Surged - etf.com
Best ETFs of Last Week - Yahoo Finance
US stocks waver, extending tech-led selloff - Yahoo Singapore News
Time for Healthcare ETFs? - Yahoo Finance
TSLA-related ETFs among top performing ETFs on a 4-week performance base last week - MSN
5 Top ETFs of Last Week - Yahoo Finance
US consumer inflation eases more than expected - Yahoo Singapore News
How the (CNCR) price action is used to our Advantage - Stock Traders Daily
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly - Yahoo Finance
All you need to know about: Malaysia’s new cost-of-living benchmark - Yahoo News Malaysia
HHLHarvest ETFs: Harvest Healthcare Leaders Income ETF - The Globe and Mail
Tesla: Should You Buy the Stock Before Firm’s Q2 Deliveries Report? - Investing.com
4 Up-and-Coming Small-Cap Biotech Stocks to Watch - Investing.com
S&P 500, Nasdaq close higher to kick off second half's trading: Live updates - CNBC
(CNCR) Proactive Strategies - Stock Traders Daily
Reviewing Replimune Group (NASDAQ:REPL) and Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
7 Best Biotech ETFs to Buy Now | Investing - U.S News & World Report Money
Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive (BDTX) - Seeking Alpha
How to Invest in the Semiconductor Value Chain with These ETFs - The Globe and Mail
BMO ETFs: Balancing Growth and Income - The Globe and Mail
Oncology Stocks: 8 Biggest NASDAQ Companies in 2024 | INN - Investing News Network
Where are the Opportunities in (CNCR) - Stock Traders Daily
Finanzdaten der Range Cancer Therapeutics Etf-Aktie (CNCR)
Es liegen keine Finanzdaten für Range Cancer Therapeutics Etf (CNCR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):